摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Methyl-pamoat | 63170-41-2

中文名称
——
中文别名
——
英文名称
Methyl-pamoat
英文别名
methyl pamoate;Methyl 3-hydroxy-4-[(2-hydroxy-3-methoxycarbonylnaphthalen-1-yl)methyl]naphthalene-2-carboxylate
Methyl-pamoat化学式
CAS
63170-41-2
化学式
C25H20O6
mdl
——
分子量
416.43
InChiKey
BHFXKNGELGUNMA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    31
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    93.1
  • 氢给体数:
    2
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    Methyl-pamoat 在 lithium aluminium tetrahydride 、 三溴化磷potassium carbonateN,N-二异丙基乙胺 作用下, 以 四氢呋喃二氯甲烷乙酸乙酯丙酮 为溶剂, 反应 210.0h, 生成 N,N,N-bis(2-picolyl)-(2,2'-[1,2-ethanediylbis(oxy)]-1,1'-dinaphthylmethane-3,3'-methyl) amine
    参考文献:
    名称:
    双核铜(II)配合物1:磷酸酶样活性中新配合物的合成,表征和评估
    摘要:
    摘要合成了一种新的双核型铜双价铜配合物,并通过X射线晶体学对其进行了表征。检查该络合物作为双(对硝基苯基)磷酸酯水解中的催化剂。在各种pH下研究了其催化性能,并将其与单核Cu(II)配合物进行了比较。在pH 5.38时,双核Cu(II)络合物显示出具有11 TON和24%转化率的磷酸酶样活性,并且发现其活性比单核对应物高41倍。
    DOI:
    10.1016/j.ica.2012.04.019
点击查看最新优质反应信息

文献信息

  • [EN] A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE PAMOATE DE PYRVINIUM ET DE FORMES CRISTALLINES DE CELUI-CI
    申请人:URQUIMA SA
    公开号:WO2017178524A1
    公开(公告)日:2017-10-19
    The present invention relates to a process for the preparation of pyrvinium pamoate, which comprises reacting pyrvinium methyl sulphate salt of formula (II) with disodium pamoate of formula (III), in the presence of a base; to processes for the preparation of crystalline Form A and crystalline Form III of pyrvinium pamoate; as well as a process for the purification of crystalline Form III. It also relates to crystalline Forms A and III of pyrvinium pamoate and to pharmaceutical compositions containing them.
    本发明涉及一种用于制备吡替硫酸吡替硫盐的方法,包括在碱的存在下,将化学式(II)的吡替硫酸甲基硫酸盐与化学式(III)的二钠吡替硫酸盐反应;以及制备吡替硫酸吡替硫晶型A和晶型III的方法;以及一种用于净化晶型III的方法。本发明还涉及吡替硫酸吡替硫晶型A和晶型III,以及含有它们的药物组合物。
  • A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF
    申请人:Urquima S.A.
    公开号:EP3231796A1
    公开(公告)日:2017-10-18
    The present invention relates to a process for the preparation of pyrvinium pamoate, which comprises reacting pyrvinium methyl sulphate salt of formula (II) with disodium pamoate of formula (III), in the presence of a base; to processes for the preparation of crystalline Form A and crystalline Form III of pyrvinium pamoate; as well as a process for the purification of crystalline Form III. It also relates to crystalline Forms A and III of pyrvinium pamoate and to pharmaceutical compositions containing them.
    本发明涉及一种制备吡维溴铵帕莫酸盐的方法,其包括在碱的存在下,将式(II)的吡维溴铵甲基硫酸盐与式(III)的双钠帕莫酸盐反应;以及制备吡维溴铵帕莫酸盐的结晶形式A和结晶形式III的方法。同时还涉及一种纯化结晶形式III的方法。本发明还涉及吡维溴铵帕莫酸盐的结晶形式A和结晶形式III,以及含有它们的制药组合物。
  • Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
    申请人:K.U. LEUVEN RESEARCH & DEVELOPMENT
    公开号:EP0998946A1
    公开(公告)日:2000-05-10
    The invention relates to a non porphyrin compound or a pharmaceutically acceptable salt thereof, suitable for in vitro, in vivo and/or ex vivo use as a diagnosticum and/or pharmaceutical, said compound comprising: a targeting agent for targeting a specific area, such as an organ and/or tissue, a labelling agent L for labelling the targeted area; said targeting agent being connected to the labelling agent L, wherein said targeting agent comprises one or more substituted and/or unsubstituted organic ring compounds.
    本发明涉及一种非卟啉化合物或其药学上可接受的盐,适用于体外、体内和/或体外诊断和/或制药,所述化合物包括 靶向剂,用于靶向特定区域,如器官和/或组织、 用于标记目标区域的标记剂 L;所述靶向剂与标记剂 L 连接、 其中,所述靶向剂包括一种或多种取代和/或未取代的有机环化合物。
  • [EN] NON-PORPHYRIN COMPOUND FOR USE AS A DIAGNOSTICUM AND/OR PHARMACEUTICAL<br/>[FR] COMPOSE NON PORPHYRINE UTILISE A DES FINS DIAGNOSTIQUES ET/OU PHARMACEUTIQUES
    申请人:LEUVEN K U RES & DEV
    公开号:WO2000009169A1
    公开(公告)日:2000-02-24
    The invention relates to a non porphyrin compound or a pharmaceutically acceptable salt thereof, suitable for in vitro, in vivo and/or ex vivo use as a diagnosticum and/or pharmaceutical, said compound comprising: a targeting agent for targeting a specific area, such as an organ and/or tissue, a labelling agent L for labelling the targeted area; said targeting agent being connected to the labelling agent L, wherein said targeting agent comprises one or more substituted and/or unsubstituted organic ring compounds.
  • Binuclear copper(II) complexes 1: Synthesis, characterization and evaluation of a new complex in phosphatase-like activity
    作者:Olivier Schicke、Bruno Faure、Michel Giorgi、A. Jalila Simaan、Marius Réglier
    DOI:10.1016/j.ica.2012.04.019
    日期:2012.8
    Abstract A new binuclear Cu(II) complex derived from a pamoic type ligand has been synthesized and characterized by X-ray crystallography. This complex was checked as catalysts in the hydrolysis of bis(p-nitrophenyl)phosphate. Its catalytic properties were studied at various pH and compared to the mononuclear Cu(II) complex. At pH 5.38, the binuclear Cu(II) complex exhibited a phosphatase-like activity
    摘要合成了一种新的双核型铜双价铜配合物,并通过X射线晶体学对其进行了表征。检查该络合物作为双(对硝基苯基)磷酸酯水解中的催化剂。在各种pH下研究了其催化性能,并将其与单核Cu(II)配合物进行了比较。在pH 5.38时,双核Cu(II)络合物显示出具有11 TON和24%转化率的磷酸酶样活性,并且发现其活性比单核对应物高41倍。
查看更多